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Leukemia cutis (LC), the infiltration of the epidermis, dermis, or subcutis with leukemia cells, complicates 5-10% of cases of acute myeloid leukemia (AML) in adults and is considered a marker of poor prognosis. [1] [2] [3] While the association between AML with monocytic features and LC has been described, little is known about the association of other AML characteristics and LC. 2, 4, 5 Recently, a number of recurrent gene mutations have been described in AML;
however, the association of these mutations and LC has not been systematically investigated. 6, 7 Using amplicon-based next-generation sequencing (NGS) of a panel of recurrent, hematologic malignancy-associated mutations, we sought to determine the association between molecular markers and LC.
We identified 284 patients diagnosed with AML at the University of The presence of an NPM1 mutation was associated with LC (OR: 2.9; 95% CI: 1.3-6.6, P=0.009), as 14 of 27 cases of LC had an NPM1 mutation (all the common exon 12 insertion). An association between PTPN11 and LC was also detected (OR: 3.6; P=0.014); however, 4 of the 6 cases of LC in patients with a PTPN11 mutation also had a concurrent NPM1 mutation. No association was detected between LC and presence of any other myeloid malignancyassociated mutations or functional class of mutations (Table 2) . We further examined the association of NPM1 mutation status and LC in an expanded cohort of patients with known NPM1 mutant status. Characteristics of the expanded cohort are similar to the initial cohort ( The true incidence of LC has been difficult to define as reports have been limited by small numbers of patients with varying demographic characteristics.
This study is among the largest single-center reviews of LC in AML. Biopsy proven LC was found in 10% of patients in this large cohort, which appears to be higher than some previously reported series in adult AML patients. This suggests that LC is a more common complication of adult AML than sometimes reported.
1- 6 3 This higher incidence in our cohort may also be a reflection of increased surveillance and clinician suspicion of the condition in our institution.
We identified a unique association between NPM1 mutation status and the presence of LC among patients with AML with monocytic features. We first identified this finding in a cohort of 284 patients who had undergone extended mutation testing and then confirmed the association in an expanded cohort of 560 AML patients with known NPM1 mutant status. Interestingly, although we
show an association between NPM1 and LC, we did not confirm an independent association between monocytic features and LC.
Our study is limited by its retrospective nature -not all patients were prospectively monitored, particularly from a dermatologic perspective, and therefore our data likely represents an under-ascertainment of LC. It is also The implication of having both of these prognostic features is unknown and should be the subject of further investigation.
The cellular mechanisms through which NPM1 mutations might alter leukemic myeloblasts' homing to skin require further study. Regardless of mechanism, our data support the World Health Organization's provisional classification of NPM1-mutated AML as a distinct biologic entity. We note that an association between NPM1 mutation and myeloid sarcomas has previously been described supporting the unique biology of NPM1-mutated AML. 13 In summary, our data suggests that the previously described association between AML with monocytic features and LC may largely be explained by an association between NPM1 and LC. 
